Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Novavax (NVAX) PT Raised to $38 at Ladenburg Thalmann
May 12, 2020 8:19 AM EDTLadenburg Thalmann analyst Michael Higgins raised the price target on Novavax (NASDAQ: NVAX) to $38.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "Last night, Novavax announced its 1Q20 results, presenting a $0.58 loss per share, better than our estimate of -$0.77... More
Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat
May 11, 2020 5:04 PM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($0.58), $0.20 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $3.38 million versus the consensus estimate of $1.74 million.
Our accomplishments to-date in 2020, including significant progress in our influenza and COVID19 vaccine programs, are the most... More
